New clot busters threaten Genentech's tPA.
Davidson
S
S
D001709:Biotechnology; D002986:Clinical Trials as Topic; D015195:Drug Design; D004345:Drug Industry; D005343:Fibrinolytic Agents / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D010960:Plasminogen Activators / Q000493:pharmacokinetics / Q000627:therapeutic use; D011655:Pulmonary Embolism / Q000188:drug therapy; D011994:Recombinant Proteins / Q000493:pharmacokinetics / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014481:United States
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; C087896:reteplase; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator